Shopping Cart 0
Cart Subtotal
USD 0

Presbyopia-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Presbyopia-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia-Pipeline Review, H2 2017, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.

Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 5, 1 and 2 respectively.

Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Presbyopia-Overview

Presbyopia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Presbyopia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Presbyopia-Companies Involved in Therapeutics Development

Acucela Inc

Allergan Plc

Johnson & Johnson

Novartis AG

Presbyopia-Drug Profiles

(aceclidine + tropicamide)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diclofenac sodium + pilocarpine hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(oxymetazoline hydrochloride + pilocarpine hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-06-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanosterol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxymetazoline hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta-L Crystallin for Cataract and Presbyopia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Presbyopia-Product Development Milestones

Featured News & Press Releases

May 05, 2016: Encore Vision Announces Successful Phase I-II Study of Topical EV06 for the Treatment of Presbyopia

May 02, 2016: Encore Vision Announces Positive Results from the Phase I-II Study of Topical EV06 for the Treatment of Presbyopia

Jan 25, 2016: Encore Vision Announces Completion of Target Enrollment

Oct 05, 2015: Encore Vision Announces First Subject Enrolled in Study of Topical Treatment for Presbyopia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Presbyopia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Presbyopia, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Presbyopia-Pipeline by Acucela Inc, H2 2017

Presbyopia-Pipeline by Allergan Plc, H2 2017

Presbyopia-Pipeline by Johnson & Johnson, H2 2017

Presbyopia-Pipeline by Novartis AG, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Acucela Inc

Allergan Plc

Johnson & Johnson

Novartis AG